Exchange: NASDAQ·Updated 09:41 AM EDT
News
all
press releases
3 Generic Drug Stocks to Watch Amid Improving Industry Trends
The Medical - Generic Drugs industry gains from new launches, biosimilar momentum and portfolio shifts, despite pricing pressure and supply challenges.
Zacks
More News
Here's Why Viatris (VTRS) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
Viatris (VTRS) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?
Amneal enters the second half of 2026 with higher guidance and a broader pipeline, but Rytary erosion and execution risks raise the stakes.
Zacks
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks
Theravance's Q2 earnings match estimates. Cost cuts and a $929 million Zymeworks deal follow ampreloxetine's discontinuation.
Zacks
Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook
Viatris sells Tyrvaya to Harrow for up to $100 million, raises 2026 guidance after second-quarter earnings and revenue beat estimates.read more...
Benzinga
VTRS Q2 Earnings Beat, Revenues Rise 5% as Greater China Sales Jump
Viatris tops Q2 earnings and revenue estimates as Greater China sales surge 21%, helping lift results and prompting a higher 2026 financial outlook.
Zacks
Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Viatris (VTRS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks
Viatris (VTRS) Beats Q2 Earnings and Revenue Estimates
Viatris (VTRS) delivered earnings and revenue surprises of +11.29% and +2.19%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Viatris Posts Wider Loss In Q2; Raises 2026 Guidance
(RTTNews) - Viatris Inc. (VTRS) reported a second-quarter net loss of $118.8 million compared to a net loss of $4.6 million, a year ago. GAAP diluted loss per share was $0.10 compared to a loss of less than $0.01 per share. The loss in the second quarter was primarily driven by a...
Nasdaq News: Markets

Advertisement|Remove ads.